生物活性

Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has?EC50s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for?SARS-CoV-2?and its variants alpha, beta, gamma and delta, respectively. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2][3].

IC50?& Target

EC50: 30 nM (murine hepatitis virus, delayed brain tumor cell), 74 nM (SARS-CoV, HAE cell), 74 nM (MERS-CoV, HAE cell)[1]
EC50: 3.3 μM (SARS-CoV-2), 4.7 μM (SARS-CoV-2 alpha), 32 μM (SARS-CoV-2 beta), 3.7 μM (SARS-CoV-2 gamma) and 9.2 μM (SARS-CoV-2 delta)[3]

体外研究
(In Vitro)

Remdesivir (GS-5734) inhibits murine hepatitis virus (MHV) with an EC50?of 30 nM, and blocks SARS-CoV and MERS-CoV in HAE cells with EC50s of both 74 nM in HAE cells after treatment for 24 h[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number

Sponsor

Condition

Start Date

Phase

NCT04865237

Imperial College London|Hvivo|Royal Free Hospital NHS Foundation Trust

Covid19|SARS-CoV Infection|Corona Virus Infection|Coronavirus|COVID-19

March 6, 2021

Not Applicable

NCT04693026

M Abdur Rahim Medical College and Hospital|First affiliated Hospital Xi′an Jiaoting University

Covid19|Covid-19 ARDS

September 10, 2020

Phase 3

NCT04292899

Gilead Sciences

COVID-19

March 6, 2020

Phase 3

分子量

602.58

Formula

C27H35N6O8P

CAS 号

1809249-37-3

中文名称

瑞德西韦

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder

-20°C

3 years

In solvent

-80°C

6 months

-20°C

1 month

溶解性数据

In Vitro:?

DMSO : 100 mg/mL?(165.95 mM;?Need ultrasonic)

配制储备液

浓度溶剂体积质量

1 mg

5 mg

10 mg

1 mM

1.6595 mL

8.2977 mL

16.5953 mL

5 mM

0.3319 mL

1.6595 mL

3.3191 mL

10 mM

0.1660 mL

0.8298 mL

1.6595 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

D、销售的所有产品均不得用于人类或动物之临床诊断或治疗，仅可用于工业或者科研等非医疗目的。